Trontinemab  (Synonyms: RG6102; RO-7126209)

Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1^[1][2][3][4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Amyloid beta A4 precursor protein, APP; Transferrin receptor, TFRC

Trontinemab (0-5 μg/mL, 45 分钟) 通过 Fc 受体介导的吞噬作用修饰的 Aβ 斑块是人类巨噬细胞清除 Aβ 斑块的一种主要机制^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Trontinemab (20 µg/mL) 在 FcgR 人源化小鼠中与 TFR 结合可诱导首次输注反应 (FIRs)，并通过 FC 介导的效应物功能刺激细胞因子释放^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2568868-35-7

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-(Fab G1-kappa with domain crossover)

• 
  Immobilized Human Beta-amyloid/Beta-APP Protein (hFc Tag) can bind Trontinemab. The EC₅₀ for this effect is 34.64 ng/mL.

• [1]. Neațu M, et al. Monoclonal Antibody Therapy in Alzheimer's Disease. Pharmaceutics. 2023 Dec 29;16(1):60.  [Content Brief]

  [2]. Trontinemab. IMGT/mAb-DB.

  [3]. Weber F, et al. Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode. Cell Rep. 2018 Jan 2;22(1):149-162.  [Content Brief]

  [4]. Roche H L. Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants with Prodromal or Mild to Moderate Alzheimer’s Disease[J]. ClinicalTrialsgov Identifier: NCT04639050, 2021, 2024.